For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > COMMENTARY
COMMENTARY
-
Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
-
Pinning Hope on Academia in Seeking a Radical Cure for AD
October 10, 2011
-
New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
October 3, 2011
-
Discussions on Amendment of PAL Now in Final Stages
October 3, 2011
-
Korosho Revises GL for Drafting, Distributing Drug Safety Information
September 5, 2011
-
Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
-
Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
-
Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
-
Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
July 18, 2011
-
Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
-
Era of Competition Dawns in Market for AD Treatments
June 27, 2011
-
Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
June 20, 2011
-
Return to Full-bore Growth Strategy Risky for Taiyo Pharm
June 13, 2011
-
Why the Same Mistake Repeated? -MSD's Promotion Code Violations
June 6, 2011
-
GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
-
Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
-
Japan's Most Admired Pharma Companies in 2010
April 4, 2011
-
Will New Disclosure GL Promote Industry-Academia Alliances?
March 28, 2011
-
Use of Generics by Welfare Recipients
March 7, 2011
-
Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
February 21, 2011
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…